TOKYO – The Japanese government said a letter it wrote to the EU and Britain expressing trepidation about the future of the region after the U.K. voted to leave the union – a decision known as the Brexit – was penned after discussions with companies of all sizes. (See BioWorld Today, Sept. 14, 2016.)
TOKYO – Despite numerous obstacles standing in the way of companies making progress, Japan's biosimilars market is likely to grow in the coming years, driven both by rising awareness of the value of no-brand drugs and an industry body that is driving growth.
TOKYO – Despite numerous obstacles standing in the way of companies making progress, Japan's biosimilars market is likely to grow in the coming years, driven both by rising awareness of the value of no-brand drugs and an industry body that is driving growth.
TOKYO – Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, will attempt to develop a vaccine to tackle the Zika virus with funding from the U.S. government worth up to $311 million.
TOKYO – Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, will attempt to develop a vaccine to tackle the Zika virus with funding from the U.S. government worth up to $311 million.
TOKYO – Toshiba Corp. is developing a treatment for cancer that uses particle beams and will send the technology to trial next year, aiming to have a device on the market by the early 2020s.
TOKYO – Takeda Pharmaceutical Co. Ltd., of Japan, plans to restructure its research and development operations to focus primarily on the areas of oncology, gastroenterology and central nervous system, as well as vaccines. To accommodate the mission, R&D facilities in Japan and the U.S. will be expanded, while those in other areas of the world face risk of closure, including the U.K.
